• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bausch + Lomb makes another eye drop acquisition

July 6, 2023 By Sean Whooley

Bausch + Lomb (1)Bausch + Lomb (NYSE:BLCO) announced today that an affiliate purchased the Blink product line from Johnson & Johnson Vision.

The over-the-counter Blink product line features eye and contact lens drops, marking another eye care acquisition for Bausch + Lomb. Last week, the company acquired eye drops and a delivery system from Novartis in a deal worth up to $2.5 billion.

Under the terms of this deal, Bausch + Lomb plans to use cash on hand to acquire the Blink line for $106.5 million.

“There’s a growing need for relieving the symptoms of dry eyes and dry contact lenses, and OTC products are often the first option consumers choose,” said John Ferris, EVP, Consumer, Bausch + Lomb. “The addition of Blink expands our robust portfolio of OTC eye care brands, enabling us to provide more choices for consumers and eye care professionals.”

Blink features a variety of eye drops and contact lens resetting drops. They provide immediate and long-lasting symptom relief.

Products involved in the acquisition include:

  • Blink Tears Lubricating Eye Drops;
  • Blink Tears Preservative Free Lubricating Eye Drops;
  • Blink GelTears Lubricating Eye Drops;
  • Blink Triple Care Lubricating Eye Drops;
  • Blink Contacts Lubricating Eye Drops; and
  • Blink-N-Clean Lens Drops.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Optical/Ophthalmic Tagged With: bausch&lomb, Johnson & Johnson Vision

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS